【制药网 企业新闻】在全球医疗健康领域,创新药的研发始终是推动行业进步、改善患者生命质量的核心动力。近日,复星医药与梯瓦(Teva Pharmaceutical Industries Ltd.)达成的一项重磅战略合作,再次将行业目光聚焦于复星医药在创新药领域的积极探索与战略布局。双方宣布,将通过各自子公司,共同开发在研药物抗 PD1 - IL2 ATTENUKINE™疗法 TEV-56278,这一...
Source Link【制药网 企业新闻】在全球医疗健康领域,创新药的研发始终是推动行业进步、改善患者生命质量的核心动力。近日,复星医药与梯瓦(Teva Pharmaceutical Industries Ltd.)达成的一项重磅战略合作,再次将行业目光聚焦于复星医药在创新药领域的积极探索与战略布局。双方宣布,将通过各自子公司,共同开发在研药物抗 PD1 - IL2 ATTENUKINE™疗法 TEV-56278,这一...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.